rs1085307409
Variant summary
Our verdict is Pathogenic. Variant got 15 ACMG points: 15P and 0B. PM2PP2PP3_StrongPP5_Very_Strong
The NM_000020.3(ACVRL1):āc.818T>Cā(p.Leu273Pro) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.000000684 in 1,461,834 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. 12/21 in silico tools predict a damaging outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (ā ā ).
Frequency
Consequence
NM_000020.3 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 15 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
ACVRL1 | NM_000020.3 | c.818T>C | p.Leu273Pro | missense_variant | Exon 7 of 10 | ENST00000388922.9 | NP_000011.2 |
Ensembl
Frequencies
GnomAD3 genomes Cov.: 33
GnomAD4 exome AF: 6.84e-7 AC: 1AN: 1461834Hom.: 0 Cov.: 32 AF XY: 0.00 AC XY: 0AN XY: 727212
GnomAD4 genome Cov.: 33
ClinVar
Submissions by phenotype
Telangiectasia, hereditary hemorrhagic, type 2 Pathogenic:2
Pathogenic, criteria provided, single submitter | clinical testing | ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories | Jan 30, 2024 | The ACVRL1 c.818T>C; p.Leu273Pro variant (rs1085307409) is reported in the literature in individuals with suspected HHT and shown to segregate with disease in affected family members (Abdalla 2005, Kitonyi 2008, Machado 2015, Smoot 2009, Westermann 2011). This variant is also reported in ClinVar (Variation ID: 426017). This variant is absent from the Genome Aggregation Database (v2.1.1), indicating it is not a common polymorphism. Computational analyses predict that this variant is deleterious (REVEL: 0.776). Based on available information, this variant is considered to be pathogenic. References: Abdalla SA et al. Novel mutations and polymorphisms in genes causing hereditary hemorrhagic telangiectasia. Hum Mutat. 2005 Mar;25(3):320-1. PMID: 15712271. Kitonyi GW et al. Hereditary haemorrhagic telangiectasia in a black adult male: case report. East Afr Med J. 2008 Aug;85(8):412-6. PMID: 19115559. Machado RD et al. Pulmonary Arterial Hypertension: A Current Perspective on Established and Emerging Molecular Genetic Defects. Hum Mutat. 2015 Dec;36(12):1113-27. PMID: 26387786. Smoot LB et al. Clinical features of pulmonary arterial hypertension in young people with an ALK1 mutation and hereditary haemorrhagic telangiectasia. Arch Dis Child. 2009 Jul;94(7):506-11. PMID: 19357124. Westermann CJ et al. Is hereditary haemorrhagic telangiectasia rare in the black race? The first sub-Saharan mutation. Haemophilia. 2011 Jan;17(1):e244. PMID: 20609011. - |
Likely pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | May 09, 2024 | This sequence change replaces leucine, which is neutral and non-polar, with proline, which is neutral and non-polar, at codon 273 of the ACVRL1 protein (p.Leu273Pro). This variant is not present in population databases (gnomAD no frequency). This missense change has been observed in individual(s) with clinical features of hereditary hemorrhagic telangiectasia (PMID: 15712271). It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 426017). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt ACVRL1 protein function with a positive predictive value of 95%. In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic. - |
Pulmonary arterial hypertension related to hereditary hemorrhagic telangiectasia Pathogenic:1
Pathogenic, no assertion criteria provided | literature only | Rare Disease Genomics Group, St George's University of London | - | - - |
Hereditary hemorrhagic telangiectasia Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine | Dec 09, 2014 | The p.Leu273Pro variant in ACVRL1 has been reported in 3 individuals with Hereditary Hemorrhagic Telangiectasia (HHT) and segregated with disease in 7 affected relatives from 2 families (Abdalla 2005, Smoot 2009, Westerman 2011). It was absent from large population studies. Computational prediction tools and conservation analysis suggest that the p.Leu273Pro variant may impact the protein, though this information is not predictive enough to determine pathogenicity. In summary, this variant meets our criteria to be classified as pathogenic for hereditary hemorrhagic telangiectasia in an autosomal dominant manner (http://www.partners.org/personalizedmedicine/LMM) based upon segregation studies. - |
Cardiovascular phenotype Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Jul 15, 2021 | The p.L273P pathogenic mutation (also known as c.818T>C), located in coding exon 6 of the ACVRL1 gene, results from a T to C substitution at nucleotide position 818. The leucine at codon 273 is replaced by proline, an amino acid with similar properties. This mutation was described in a child with pulmonary arteriovenous malformation (PAVM) and was found to track with disease in the affected mother, grandmother, and maternal aunt (Abdalla SA et al. Hum. Mutat., 2005 Mar;25:320-1). In another study, this mutation was also described in a child presenting with pulmonary arterial hypertension and a PAVM; the mutation also tracked in clinically affected family members (Smoot LB et al. Arch. Dis. Child., 2009 Jul;94:506-11). This mutation was identified in a Kenyan male with epistaxis, telangiectasias, and a family history of epistaxis (Kitonyi GW et al. East Afr Med J, 2008 Aug;85:412-6; Westermann CJ et al. Haemophilia, 2011 Jan;17:e244). Based on the supporting evidence, this alteration is interpreted as a disease-causing mutation. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at